Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Unilever investment

This article was originally published in The Rose Sheet

Executive Summary

Unilever dedicating nearly $170 mil. to corporate ventures to build business opportunities in food and home and personal care, company announces Sept. 30. Majority of the funding - nearly $100 mil. - will be dedicated to Langholm Capital Partners Fund, which will target investments in mid-market European consumer-facing businesses, Unilever says. Additionally, firm will invest almost $40 mil. over three years in Unilever Ventures, "an early stage business development fund supporting early stage business ideas," company says. Nearly $30 mil. will be used to identify and invest in technology-based funds and start up companies via Unilever Technology Ventures. Goal is to "enhance the scope and quality of Unilever's own R&D activities by exploiting new technologies," company says, noting areas of investment will include genomics, advanced bioscience, advanced materials science and nanotechnology...
Advertisement
Advertisement
UsernamePublicRestriction

Register

RS010660

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel